Evidence map›Paper›PMID 15247165›Full record

ArticleGut2004

Effects of growth factors and receptor blockade on gastrointestinal cancer.

R J Playford, H Wassan, S Ghosh

Abstract read
In one paragraph

Article in Gut, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

R J PlayfordGastroenterology Section, Division of Medicine, Imperial College London, Hammersmith Hospital, London, UK. r.playford@imperial.ac.uk
H Wassan
S Ghosh

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of recombinant peptide technology offers the potential to use one or several peptides to treat a variety of gastrointestinal conditions. However, although cell culture and animal models have shown proof of concept, we are still at a relatively early stage in translating their use to standard clinical practice. Similarly, peptide and non-peptide antagonists of growth factor receptors show great potential as novel antichemotherapy agents. However, their actual place in clinical practice has yet to be established.

Indexed as

ErbB ReceptorsGastrointestinal NeoplasmsGrowth InhibitorsGrowth SubstancesHumansPeptidesReceptors, Growth FactorRecombination, GeneticRisk FactorsSignal TransductionErbB ReceptorsGrowth InhibitorsGrowth SubstancesPeptidesReceptors, Growth Factor

Identifiers

PMID15247165
PMCPMC1774142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.